285 related articles for article (PubMed ID: 10504731)
1. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
2. Blocking HIV entry.
Buzko OV; Shokat KM
Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
[TBL] [Abstract][Full Text] [Related]
3. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
4. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
[TBL] [Abstract][Full Text] [Related]
5. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
Kliger Y; Shai Y
J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
[TBL] [Abstract][Full Text] [Related]
8. Capture of an early fusion-active conformation of HIV-1 gp41.
Furuta RA; Wild CT; Weng Y; Weiss CD
Nat Struct Biol; 1998 Apr; 5(4):276-9. PubMed ID: 9546217
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
[TBL] [Abstract][Full Text] [Related]
10. The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core.
Zhou G; Ferrer M; Chopra R; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Harrison SC; Wiley DC
Bioorg Med Chem; 2000 Sep; 8(9):2219-27. PubMed ID: 11026535
[TBL] [Abstract][Full Text] [Related]
11. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
12. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
13. Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.
Louis JM; Bewley CA; Clore GM
J Biol Chem; 2001 Aug; 276(31):29485-9. PubMed ID: 11418583
[TBL] [Abstract][Full Text] [Related]
14. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Eckert DM; Kim PS
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11187-92. PubMed ID: 11572974
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
16. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.
Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15613-7. PubMed ID: 9861018
[TBL] [Abstract][Full Text] [Related]
17. Protein design of an HIV-1 entry inhibitor.
Root MJ; Kay MS; Kim PS
Science; 2001 Feb; 291(5505):884-8. PubMed ID: 11229405
[TBL] [Abstract][Full Text] [Related]
18. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
19. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.
Debnath AK; Radigan L; Jiang S
J Med Chem; 1999 Aug; 42(17):3203-9. PubMed ID: 10464007
[TBL] [Abstract][Full Text] [Related]
20. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
